^
    Back
    Association details:
    Biomarker:CXCL12 elevation
    Cancer:Renal Cell Carcinoma
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Am J Clin Oncol
    Title:

    Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)

    Published date:
    05/27/2020
    Excerpt:
    Among patients experiencing PD, the median plasma levels of stromal derived factor-1 and vascular endothelial growth factor-A were significantly higher compared with the baseline (P=0.01; P=0.011). Changes in levels of selected CAFs were associated with response/resistance to pazopanib in mRCC patients.
    DOI:
    10.1097/COC.0000000000000719
    Trial ID:
    PIPELINE